Department of Neurosurgery, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, People's Republic of China.
Department of Neurosurgery, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, People's Republic of China
J Investig Med. 2022 Jun;70(5):1273-1279. doi: 10.1136/jim-2021-002230. Epub 2022 Mar 25.
This study aims to evaluate the efficacy and safety of endovascular therapy versus neurosurgical clipping carried out for patients with unruptured middle cerebral artery bifurcation aneurysms (MCABAs). Patients diagnosed with MCABAs were enrolled in this prospective study according to the inclusion and exclusion standard. Enrolled patients were divided into a study group (endovascular therapy) and a control group (neurosurgical clipping), with 65 cases in each group. In terms of efficacy, we found that the proportion of Glasgow Outcome Scale (GOS) grade 1 after treatment in the study group was significantly higher than in the control group (p<0.001), while the proportion of GOS grades 2, 3, and 4 after treatment was significantly lower in the study group than in the control group (p<0.05). The postoperative brain injury indicators neuron-specific enolase and S100β in the study group were significantly lower than in the control group (p<0.001), and the postoperative life activity score of patients in the study group was significantly higher than in the control group (p<0.001). In terms of safety, the postoperative hospital stay of patients in the study group was significantly shorter than in the control group (p<0.001), and the incidence rate of postoperative pulmonary and intracranial infections in the study group was significantly lower than in the control group (p<0.05). Endovascular therapy for patients with unruptured MCABAs may be effective in improving outcomes and has better safety profile compared with neurosurgical clipping, but may increase the risk of postoperative recurrence.
本研究旨在评估血管内治疗与神经外科夹闭治疗未破裂大脑中动脉分叉部动脉瘤(MCA-BA)患者的疗效和安全性。根据纳入和排除标准,将诊断为 MCA-BA 的患者纳入前瞻性研究。将纳入的患者分为研究组(血管内治疗)和对照组(神经外科夹闭),每组 65 例。在疗效方面,我们发现治疗后研究组格拉斯哥预后量表(GOS)评分 1 级的比例明显高于对照组(p<0.001),而治疗后 GOS 评分 2、3、4 级的比例明显低于对照组(p<0.05)。研究组术后脑损伤标志物神经元特异性烯醇化酶和 S100β明显低于对照组(p<0.001),研究组患者术后生活活动评分明显高于对照组(p<0.001)。在安全性方面,研究组患者术后住院时间明显短于对照组(p<0.001),研究组术后肺部和颅内感染发生率明显低于对照组(p<0.05)。血管内治疗未破裂 MCA-BA 患者可能在改善预后方面有效,且与神经外科夹闭相比具有更好的安全性,但可能增加术后复发的风险。